tradingkey.logo

Grail Inc

GRAL
100.070USD
+6.010+6.39%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
3.62BMarktkapitalisierung
VerlustKGV TTM

Grail Inc

100.070
+6.010+6.39%

mehr Informationen über Grail Inc Unternehmen

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Grail Inc Informationen

BörsenkürzelGRAL
Name des UnternehmensGrail Inc
IPO-datumJun 12, 2024
CEORagusa (Robert)
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
Addresse1525 O'brien Drive
StadtMENLO PARK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94025
Telefon18336942553
Websitehttps://grail.com/
BörsenkürzelGRAL
IPO-datumJun 12, 2024
CEORagusa (Robert)

Führungskräfte von Grail Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Screening
32.81M
90.64%
Development Services
3.39M
9.36%
Nach RegionUSD
Name
Umsatz
Anteil
United States
32.65M
90.20%
International
3.55M
9.80%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Screening
32.81M
90.64%
Development Services
3.39M
9.36%

Aktionärsstatistik

Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
Andere
70.71%
Aktionäre
Aktionäre
Anteil
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
Andere
70.71%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
26.31%
Investment Advisor/Hedge Fund
21.22%
Hedge Fund
13.43%
Corporation
8.98%
Research Firm
4.26%
Individual Investor
1.06%
Bank and Trust
0.38%
Venture Capital
0.38%
Pension Fund
0.27%
Andere
23.71%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
989
25.81M
66.22%
-6.45M
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Illumina Inc
3.50M
8.98%
-1.00M
-22.21%
Nov 17, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
5.45%
+37.64K
+1.81%
Sep 30, 2025
PRIMECAP Management Company
2.02M
5.18%
-33.35K
-1.62%
Sep 30, 2025
The Vanguard Group, Inc.
1.81M
4.64%
-85.37K
-4.50%
Sep 30, 2025
CRCM L.P.
1.80M
4.62%
-42.00K
-2.28%
Oct 06, 2025
Baker Bros. Advisors LP
1.63M
4.18%
--
--
Sep 30, 2025
Farallon Capital Management, L.L.C.
1.61M
4.13%
+232.00K
+16.85%
Nov 17, 2025
State Street Investment Management (US)
1.32M
3.38%
+69.55K
+5.58%
Sep 30, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.66%
-2.00K
-0.19%
Sep 30, 2025
Sessa Capital
786.14K
2.02%
--
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
Mehr Anzeigen
ROBO Global Healthcare Technology & Innovation ETF
Anteil3.75%
Clough Select Equity ETF
Anteil2.7%
Clough Hedged Equity ETF
Anteil2.53%
Franklin Genomic Advancements ETF
Anteil2.49%
First Trust Small Cap Growth AlphaDEX Fund
Anteil1.08%
State Street SPDR S&P Biotech ETF
Anteil0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.59%
ProShares Ultra Nasdaq Biotechnology
Anteil0.48%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.42%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI